Replies to post #170659 on Avid Bioservices Inc (CDMO)

[goodplenty100]

It is because of these types of posts at this particular time, that has me following you as one of the most valued posters on this board. Your contributions are always noticed and appreciated.
Much thanks.

[PGG76109]

This is why I keep adding month by month year by year one day baby! PG

PS still want to get over 100K not too far away some buying needs to be done.

[Protector]

biopharm, I am not sure we will get a separate PR on the start of recruitment in this new Bavi Immuno related trial.

I think it will be mentioned in the AACR presentations.

This may be a faster way to follow the start of recruitment.

An update run is scheduled for today, so somewhere during the day or tomorrow morning we may see if the trial has started to recruit. For that PPHM needed to start it past week.

If they start it today, and if they don't PR it, we will normally see it the earliest on the scheduled mid-week records update.

Always remember that what you see has a 1 to 5 days possible delay (latency), therefore you need to rely on the date at the top of the document for the real last update by PPHM or UTSW, for now FEB 14, 2014.

You can check the last scheduled update run at the very bottom of the page. So as you see, what you see now dates includes the state at the last update from 27 March 2014, date at which recruitment wasn't started yet.

[biopharm]

1) July 22, 2009 ...BMS en route to scooping up Medarex ..... but not everyone was happy with that deal....

... but I'm sure BMS did not care that much, they got Adnexus for less than many investors thought they should have sold to BMS for-- and who was part of this deal? John Edwards

John Edwards has 30 years of experience in discovery, development, and global commercialization of biopharmaceuticals, involving over 10 FDA approved biologics at four successful biotechnology companies. Most recently John helped lead Adnexus from a start-up to the $450M acquisition by BMS within 4 years, where he then continued with the company for next 3 years serving as President.

www.f-star.com/about-board-john-edwards.php

... and what does F-Star, Pall Life Sciences and Peregrine Pharmaceuticals all have in common?

They are the sole 3 corporate sponsors at the 9th Annual Immunotherapies and Vaccine "ImVacs"--- and Peregrine Pharmauceuticals is now listed as one of the 3 (listed on page #2)

http://www.giievent.kr/chi296982-2014/catalog.pdf

-------------------------------------------

interesting that F-star guest speaker not listed just yet...and other than Peregrines Jeff H. presentation-- there is Omid Hamid that will be speaking about immunotherapy combo's for melanoma... hmmmm

[biopharm]

Dr. Schwartz is a highly successful business leader with a record of achievement in developing and implementing global licensing strategies to drive business growth. He as consistently achieved excellent results through the relentless pursuit of first- and/or best-in-class opportunities. An in-depth knowledge of drug development, business practices and the fields of oncology and immunology enabled the seamless execution of several key transactions (below) for Bristol-Myers Squibb. Recognized as the driving force behind the resurrection of Bristol-Myers Squibb’s oncology pipeline.
..
• Acquisition of Kosan Biosciences in May 2008
• Acquisition of Adnexus in September 2007

• Completed Compound licensing Agreements with:

- Zymogenetics (January 2009)
- Exelixis (December 2008; Allicense “Breakthrough Alliance of the Year”)
- PDL (August, 2008)
- Endocyte (March, 2006)
- Sunesis (April, 2005)
- Medarex (November, 2004)
- Pierre-Fabre (April, 2004)
- Medarex (December, 2003)

• Completed research-based collaboration agreements with:

- Infinity (December 2009)
- Adnexus Therapeutics (February, 2007; Breakthrough Alliance of 2008 )
- Exelixis (December, 2006)
- Nerviano (February (2006)
• Completed an intellectual property cross-license agreement with Roche/Kosan in February, 2006.
..

Interesting, I've already talked about a few of the deals that Bristol Myers Squibb and Robert H. Schwartz were involved in and I forgot about Exelixis, where Bruce Chabner has shares and more interesting is that Bruce Chabner has ties to Bristol Myers Squibb as well

Disclosures: Bruce A. Chabner: Sanofi, Allergan, Epizyme, PharmaMar, GlaxoSmithKline, Peregrine, Pharmacyclics (C/A); Eli Lilly (H); Gilead, Merck, Epizyme, Curis, Onyx, Bristol-Myers Squibb, Amgen, Celgene, Exelixis, Rigel (OI).

-------------------------------

This may need more looking into, because the puzzle pieces become confusing and I wonder if Bruce Chabner will become a PS Targeting advocate because now I am confused that he does not list Peregrine as a disclosure above ??

time to hit some golf balls and think about it

[biopharm]

Plaintiff:

Kenneth Blumberg -vs-


Defendants:

Howard H. Pien, Chair BOD Pres/CEO since 2007
Patricia M. Danzon, Director since 2005
Robert C. Dinerstein, Director since 2005
Marc Rubin, Director since 2007
Ronald J. Saldarini, Director since 2001
Charles R. Schaller, Director since 1987 (Chair BOD 87-97)
Julius A. Vida, Director since 1994

http://jimedwardsnrx.files.wordpress.com/2009/07/medarex-complaint.pdf

I wonder which BP will make a run for Peregrine Pharmaceuticals and I just find it interesting Howard Pien makes the rounds again.... way back accepting breadcrumb money from BMY when he sat on the BOD of Medarex....so now he sits on with JUNO and I will take SK any day of the week as a BOD to protect ones IP tech ...vs Howard Pien which was part of that BMY buyout...and remember, Medarex had collaborations with Peregrine...(so who knows what seeds were planted way back that led to Fargo sabotage...especially since BMY was involved in Medarex and hmmmm.... makes one ask many questions)
http://ir.peregrineinc.com/releasedetail.cfm?ReleaseID=266115

The puzzle of all puzzles unfolding and Peregrine, remember....you have PS Targeting that all will require to stay in business and don't forget those that made things difficult in the past while in any negotiations. : )

[biopharm]

Lets take a little history and look back at the early studies of Ipilimumab and hmmmm, could it be that Medarex actually had a nice little peek into the Ipilimumab(Yervoy)+PS targeting several years ago and then BAMM.... stomped on by a little buyout by our friendly neighbor BMS. Keep reading though... because it gets a little interesting and lets not forget that it was actually a little "David Sherris" deal from Peregrine + Medarex back in 2009 and only months later--- thats when BMS gulps down Medarex with ... hmmmm, a measly $2.9B 90% premium buyout.

So how does Dr James Allison fit in....and did BMS become concerned. Once Medarex teamed with Dr Allison..?

..After publishing his findings in 1996 in Science, Allison went looking for a pharmaceutical company to develop a CTLA-4 inhibitor for humans. He ran into a wall. Since the demise of Coley’s Toxin, several types of immunotherapy had showed promise in animal models, only to fail in people. The few that worked either had narrow applications or marginal success rates.

For two years, Allison got nothing but rejections, but his old stubbornness kept him going. At last, a small New Jersey-based company called Medarex said yes. Its scientists began working with Allison to develop the new medication. And by 2001, ipilimumab was ready for testing....

http://discovermagazine.com/2016/nov/checkmate

I will be very curious if Dr Allison OR Dr Sharma would break from the pack and realize PS Targeting is required for any chance in giving the most patients the best chance in surviving